RBC Capital raised the firm’s price target on Xenon Pharmaceuticals (XENE) to $80 from $59 and keeps an Outperform rating on the shares, citing a belief that today’s “strong” azetukalner data further increases the likelihood that the drug will be approved. The firm, which now estimates 90% odds of success, also sees higher market uptake than previously anticipated greater potential for the drug to be priced at a premium.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XENE:
- Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
- Xenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80
- Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity
- Xenon Pharmaceuticals price target raised to $97 from $63 at Baird
- Xenon Pharmaceuticals rises 46.5%